AKTX · Akari Therapeutics Plc ADR
United States · RS rating 57 · As of 2026-11-03
| Price | 8.15 USD |
|---|---|
| 1-day change | +4.0% |
| RS rating (overall / 1M / 3M / 12M) | 57 / 37 / 81 / 11 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 21 / 22 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +75.2% |
| Market cap (USD) | $6.9M |